With an estimated 40 million men in the U.S. living with benign prostatic hyperplasia, or BPH, Procept Biorobotics has developed a treatment device that certainly holds water. Literally: The AquaBeam ...
PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company’s HYDROS robotic system and consumables ...
The US Food and Drug Administration (FDA) has awarded PROCEPT BioRobotics an investigational device exemption (IDE), greenlighting a pivotal trial to test the company’s aquablation therapy to treat ...
Procept is a medical technology company offering a surgical procedure for benign prostatic hyperplasia (“BPH”), the enlargement of the prostate as a man ages, which can disrupt or block the urethra ...
Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the ...
REDWOOD CITY, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics”), a surgical robotics company focused on advancing patient care by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results